Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib vs Prednisone as First-Line Therapy for Chronic GVHD
NCT06660355Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in chronic graft-versus-host disease (cGVHD), sponsored by Moffitt Cancer Center. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06660355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660355.